You are here

  • Home
  • Online First
  • Development of a joint set of database parameters for the EU-ROP and Fight Childhood Blindness! ROP Registries

Article Text

Article menu
Download PDFPDF
Clinical science
Development of a joint set of database parameters for the EU-ROP and Fight Childhood Blindness! ROP Registries
  1. Caroline Catt1,2,
  2. Johanna M Pfeil3,
  3. Daniel Barthelmes2,4,
  4. Glen A Gole5,
  5. Tim U Krohne6,
  6. Wei-Chi Wu7,
  7. Shunji Kusaka8,
  8. Peiquan Zhao9,
  9. Shuan Dai5,
  10. James Elder10,
  11. Matthias Heckmann11,
  12. Jacqueline Stack12,
  13. Gigi Khonyongwa-Fernandez13,
  14. Andreas Stahl3
  1. 1Department of Ophthalmology, The Children's Hospital at Westmead, Westmead, New South Wales, Australia
  2. 2The Save Sight Institute, The University of Sydney, Sydney, New South Wales, Australia
  3. 3Department of Ophthalmology, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
  4. 4Department of Ophthalmology, University Hospital Zurich, Zurich, Zürich, Switzerland
  5. 5Department of Ophthalmology, Queensland Children's Hospital, Brisbane, Queensland, Australia
  6. 6Department of Ophthalmology, University of Cologne, Koln, Nordrhein-Westfalen, Germany
  7. 7Department of Ophthalmology, Chang Gung Memorial Hospital, Kweishan, Taiwan
  8. 8Department of Ophthalmology, Kindai University Faculty of Medicine Hospital, Osakasayama, Japan
  9. 9Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
  10. 10Department of Ophthalmology, Royal Children's Hospital, Parkville, Victoria, Australia
  11. 11Department of Neonatology and Pediatric Intensive Care, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
  12. 12Neonatal Intensive Care Unit, Liverpool Hospital, Liverpool, New South Wales, Australia
  13. 13Families Blossoming LLC, The Health Foundation, London, London, UK
  1. Correspondence to Caroline Catt, The Eye Clinic, The Children's Hospital at Westmead, Westmead, NSW 2145, Australia; carolinecatt{at}hotmail.com

Abstract

Background/Aims The incidence of retinopathy of prematurity (ROP) is increasing and treatment options are expanding, often without accompanying safety data. We aimed to define a minimal, patient-centred data set that is feasible to collect in clinical practice and can be used collaboratively to track and compare outcomes of ROP treatment with a view to improving patient outcomes.

Methods A multinational group of clinicians and a patient representative with expertise in ROP and registry development collaborated to develop a data set that focused on real-world parameters and outcomes that were patient centred, minimal and feasible to collect in routine clinical practice.

Results For babies receiving ROP treatment, we recommend patient demographics, systemic comorbidities, ROP status, treatment details, ophthalmic and systemic complications of treatment, ophthalmic and neurodevelopmental outcomes at initial treatment, any episodes of retreatment and follow-up examinations in the short and long-term to be collected for use in ROP studies, registries and routine clinical practice.

Conclusions We recommend these parameters to be used in registries and future studies of ROP treatment, to reduce the variation seen in previous reports and allow meaningful assessments and comparisons. They form the basis of the EU-ROP and the Fight Childhood Blindness! ROP Registries.

  • Child health (paediatrics)
  • Retina
  • Treatment Lasers
  • Treatment Surgery
  • Vision

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

http://dx.doi.org/10.1136/bjo-2023-323915

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    All data relevant to the study are included in the article or uploaded as supplementary information.

    View Full Text

    Footnotes

    • Contributors The following authors contributed to the study in the ways listed, and met all the requirements of authorship according to the ICMJE recommendations. CC: study concept and design, acquisition and analysis of results, manuscript drafting, editing and approval prior to submission and submission, and guarantor. JMP, DB and AS: study concept and design, acquisition and analysis of results, manuscript drafting, editing and approval prior to submission. GAG, W-CW, SK, PZ, SD, JE: study design, acquisition and analysis of results, manuscript editing and approval prior to submission. TUK: acquisition and analysis of results, manuscript editing and approval prior to submission. MH, JS, GK-F: acquisition of results, manuscript editing and approval prior to submission. The authors also wish to acknowledge the contributions of Dr Jesús Noel Jaurietta Hinojos, who provided a valuable opinion on the parameters during their development and Professor Mark Gillies for his guidance to the corresponding author on the study process.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests CC: previous Scientific Advisory Board membership—Novartis, Aspen. JMP: speaker—Novartis. DB: Novartis—past funding for research for the institution; Bayer—past funding for research, consultancy, paid to institution; Alcon—current, advisor, paid to author. TUK: recipient of lecture fees and consultant fees from Alimera Sciences and Roche; recipient of lecture fees from Allergan; recipient of lecture fees and consultant fees and financial support of research projects from Bayer and Novartis; recipient of lecture fees from Heidelberg Engineering. GAG, W-CW, SK, PZ, SD, JE, MH, JS, GK-F: none declared. AS: speaker: Bayer, Novartis; scientific advisory boards: Bayer, Novartis; research grants: Bayer and Novartis; clinical trials: Bayer and Novartis. The EU-ROP project is currently financed by extramural grants from the University Medicine Greifswald, solicited through the EU-ROP principal investigator from Novartis Pharma AG and Bayer Vital AG. Companies supporting the registry do not have any influence on the content or the design of the registry.The Fight Childhood Blindness! ROP Registry is a Save Sight Registry which receives funding from research and educational grants, and private donations, on a strictly non-binding basis.

    • Provenance and peer review Not commissioned; externally peer reviewed.